Immuneering Q3 net loss $14.6M; positive initial Phase 2a data for IMM-1-104

Immuneering Corp

2024-Q3 EPS reported -$1.45

Net loss $14.6M ($0.49/share) vs $12.6M ($0.43) in Q3 2023; cash $50.7M.
Positive initial Phase 2a data: complete and partial responses with IMM-1-104 + chemo in first-line pancreatic cancer.
FDA granted Orphan Drug and Fast Track designations for IMM-1-104 in pancreatic cancer.
Cash runway into Q4 2025; R&D expenses $11.3M, G&A $4.0M.
Initial data from additional Phase 2a arm and Phase 1 data for IMM-6-415 expected by year end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.